A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS4153-TPS4153 ◽  
Author(s):  
Richard S. Finn ◽  
Ann-Lii Cheng ◽  
Kenji Ikeda ◽  
Masatoshi Kudo ◽  
Toshiyuki Tamai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
Unresectable Hepatocellular Carcinoma ◽  
Open Label Phase ◽  
First Line Treatment

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

2017 ◽  
Vol 4 (6) ◽  
pp. e272-e282 ◽  
Author(s):  
Andrew Davies ◽  
Francesco Merli ◽  
Biljana Mihaljević ◽  
Santiago Mercadal ◽  
Noppadol Siritanaratkul ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
First Line Treatment

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

2014 ◽  
Vol 15 (10) ◽  
pp. 1065-1075 ◽  
Author(s):  
Volker Heinemann ◽  
Ludwig Fischer von Weikersthal ◽  
Thomas Decker ◽  
Alexander Kiani ◽  
Ursula Vehling-Kaiser ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document